Literature DB >> 7703433

Postsynaptic antagonistic interaction between adenosine A1 and dopamine D1 receptors.

S Ferré1, P Popoli, L Giménez-Llort, U B Finnman, E Martínez, A Scotti de Carolis, K Fuxe.   

Abstract

Behavioural and biochemical evidence for the existence of a powerful specific postsynaptic interaction between adenosine A1 and dopamine D1 receptors in the mammalian brain was found. Behavioural data showed that A1 receptor stimulation induced a decrease in the D1-induced motor activation in reserpinized mice and a decrease in the D1-dependent oral dyskinesia in rabbits. Biochemical data suggested that A1 receptor stimulation could produce a GTP-independent uncoupling of the rat striatal D1 receptor to the G protein. The A1-D1 receptor-receptor interaction might represent an important additional mechanism of action responsible for the motor depressant effects of adenosine agonists and for the motor stimulant effects of adenosine antagonists, like the methylxanthines caffeine and theophylline.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7703433     DOI: 10.1097/00001756-199412300-00020

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  34 in total

Review 1.  Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders.

Authors:  K Fuxe; D Marcellino; D O Borroto-Escuela; M Guescini; V Fernández-Dueñas; S Tanganelli; A Rivera; F Ciruela; L F Agnati
Journal:  CNS Neurosci Ther       Date:  2010-03-16       Impact factor: 5.243

2.  Adenosine A(1) receptor: Functional receptor-receptor interactions in the brain.

Authors:  Kathrin Sichardt; Karen Nieber
Journal:  Purinergic Signal       Date:  2007-09-05       Impact factor: 3.765

Review 3.  Adenosine hypothesis of schizophrenia--opportunities for pharmacotherapy.

Authors:  Detlev Boison; Philipp Singer; Hai-Ying Shen; Joram Feldon; Benjamin K Yee
Journal:  Neuropharmacology       Date:  2011-02-17       Impact factor: 5.250

4.  Involvement of adenosine A1 and A2A receptors on guanosine-mediated anti-tremor effects in reserpinized mice.

Authors:  C M Massari; L C Constantino; N F Marques; L B Binder; M Valle-León; M López-Cano; V Fernández-Dueñas; F Ciruela; C I Tasca
Journal:  Purinergic Signal       Date:  2020-07-28       Impact factor: 3.765

Review 5.  The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease.

Authors:  David Blum; Yijuang Chern; Maria Rosaria Domenici; Luc Buée; Chien-Yu Lin; William Rea; Sergi Ferré; Patrizia Popoli
Journal:  J Caffeine Adenosine Res       Date:  2018-06-01

Review 6.  Disease-specific heteromerization of G-protein-coupled receptors that target drugs of abuse.

Authors:  Ivone Gomes; Wakako Fujita; Moraje V Chandrakala; Lakshmi A Devi
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

7.  Stimulation of adenosine receptors in the nucleus accumbens reverses the expression of cocaine sensitization and cross-sensitization to dopamine D2 receptors in rats.

Authors:  Benjamin D Hobson; Kathryn E Merritt; Ryan K Bachtell
Journal:  Neuropharmacology       Date:  2012-06-28       Impact factor: 5.250

8.  Adenosine A1 and A2A receptors are not upstream of caffeine's dopamine D2 receptor-dependent aversive effects and dopamine-independent rewarding effects.

Authors:  Jessica E Sturgess; Ryan A Ting-A-Kee; Dominik Podbielski; Laurie H L Sellings; Jiang-Fan Chen; Derek van der Kooy
Journal:  Eur J Neurosci       Date:  2010-06-22       Impact factor: 3.386

9.  Adenosine A1-Dopamine D1 Receptor Heteromers Control the Excitability of the Spinal Motoneuron.

Authors:  Marla Rivera-Oliver; Estefanía Moreno; Yocasta Álvarez-Bagnarol; Christian Ayala-Santiago; Nicole Cruz-Reyes; Gian Carlo Molina-Castro; Stefan Clemens; Enric I Canela; Sergi Ferré; Vicent Casadó; Manuel Díaz-Ríos
Journal:  Mol Neurobiol       Date:  2018-05-24       Impact factor: 5.590

10.  Adenosine receptors as markers of brain iron deficiency: Implications for Restless Legs Syndrome.

Authors:  César Quiroz; Seema Gulyani; Wan Ruiqian; Jordi Bonaventura; Roy Cutler; Virginia Pearson; Richard P Allen; Christopher J Earley; Mark P Mattson; Sergi Ferré
Journal:  Neuropharmacology       Date:  2016-09-04       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.